168
Participants
Start Date
April 11, 2016
Primary Completion Date
January 11, 2017
Study Completion Date
December 22, 2017
50 mg of KX2-391 Ointment 1%
Dose: 50 mg; Route of administration: Topical
50 mg of KX2-391 Ointment 1%
Dose: 50 mg; Route of administration: Topical
Dermatology and Laser Center of Charleston, Charleston
Compass Research, Orlando
Clinical Research of South Florida, Coral Gables
International Dermatology Research, Miami
Palm Beach Research Center, West Palm Beach
Forward Clinical Trials, Inc., Tampa
Institute of Clinical Research - Tennessee, LLC, Murfreesboro
Minnesota Clinical Study Center, Fridley
The Center for Skin Research, Houston
J&S Studies, Inc., College Station
Clinical Trials of Texas, Inc., San Antonio
Dermatology Clinical Research Center, San Antonio
Horizons Clinical Research Center, Denver
eStudy Site, La Mesa
Palmtree Clinical Research, Inc., Palm Springs
Center for Dermatology Clinical Research, Fremont
Lead Sponsor
Collaborators (1)
Athenex, Inc.
INDUSTRY
Almirall, S.A.
INDUSTRY